Point72 Middle East FZE’s ResMed RMD Stock Holding History

Point72 Middle East FZE’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-16,962	Closed	-$3.07M	–	1812
2023 Q2	$3.71M	Buy	+16,962	New	+$3.78M	0.1%	245
2023 Q1	–	Sell	-7,267	Closed	-$1.51M	–	2111
2022 Q4	$1.51M	Buy	+7,267	New	+$1.6M	0.07%	384

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Point72 Middle East FZE's RMD Position: Q3 2023 in Review

Point72 Middle East FZE sold out of ResMed (RMD) in Q3 2023, closing a stake of 16,962 shares — an estimated $3.07M sold.

Point72 Middle East FZE first reported a position in RMD in Q4 2022 and held it in 2 quarters. The position peaked at $3.71M in Q2 2023. 657 funds tracked by Wall St. Rank hold RMD as of Q3 2023.

Point72 Middle East FZE reported no remaining ResMed position as of Q3 2023 after selling out during the quarter.
Point72 Middle East FZE sold 16,962 ResMed shares in Q3 2023, an estimated $3.07M.
Point72 Middle East FZE first reported a position in ResMed in Q4 2022 and held it in 2 quarters.
Point72 Middle East FZE's ResMed position peaked at $3.71M in Q2 2023.
657 funds tracked by Wall St. Rank held ResMed as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.